Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    Inside the Bloodbath at the NIH. Sources say that a climate of fear has spread throughout the agency as the Trump administration takes a hatchet to its core functions.

    5. Juni 2025

    Al Qaeda Refuses to Die – The Cipher Brief

    4. Juni 2025

    The Pros and Cons of Bluetooth Speakers

    4. Juni 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»Health»FDA clears first-ever blood test for Alzheimer’s diagnosis
    Health

    FDA clears first-ever blood test for Alzheimer’s diagnosis

    HealthradarBy Healthradar31. Mai 2025Keine Kommentare3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    FDA clears first-ever blood test for Alzheimer’s diagnosis
    Share
    Facebook Twitter LinkedIn Pinterest Email


    A Major Leap Toward Accessible Detection

    The U.S. Food and Drug Administration (FDA) has formally cleared the first blood test designed to help diagnose Alzheimer’s disease, marking a significant breakthrough in the diagnosis of neurodegenerative diseases. The Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio is a novel diagnostic tool that marks a significant advancement in the direction of less invasive and more accessible testing.

    Why This Blood Test Matters for Alzheimer’s Diagnosis

    PET scans and lumbar punctures, which are expensive, invasive, and not generally accessible, have been the mainstays of Alzheimer’s disease diagnosis up until this point. This recently approved blood-based Alzheimer’s test provides a more straightforward option: a routine blood draw to identify important disease-related biomarkers.

    The test measures two important blood proteins: beta-amyloid 1-42 and phosphorylated tau (pTau217). The brain’s amyloid plaques, a defining feature of Alzheimer’s disease pathology, are closely associated with these biomarkers. Clinicians can determine the probability of Alzheimer’s-related brain alterations by examining the ratio of these proteins.

    Who Can Benefit from the New Alzheimer’s Blood Test?

    The test has been cleared by the FDA for use in adults 55 years of age and older who are exhibiting cognitive symptoms like confusion or memory loss. Although the test is not a stand-alone diagnostic tool, when combined with clinical evaluation and other tests, it can yield valuable information that can support a quicker and more accurate diagnosis.

    Expert Reactions and FDA Perspective

    According to Dr. Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health, “Nearly 7 million Americans are living with Alzheimer’s disease, and that number is expected to grow significantly in the coming years. Today’s clearance is an important step in helping to obtain a timely and accurate diagnosis.”

    FDA Commissioner Robert M. Califf, M.D., added, “Alzheimer’s disease impacts too many individuals and their families. I am hopeful that new medical products such as this one can help patients get treatment started earlier, preserve cognitive function for longer, and improve their quality of life.”

    Implications for Digital Health and Future Care

    The clearance of this blood test aligns with the broader goals of digital health innovation—making diagnostics more scalable, accessible, and patient-friendly. As the global burden of Alzheimer’s continues to rise, early detection tools like this can enable earlier interventions, better care planning, and improved outcomes.

    Key Takeaways

    • FDA-cleared: First blood test to assist in Alzheimer’s diagnosis.
    • Test name: Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio.
    • Target group: Adults 55+ with signs or symptoms of cognitive impairment.
    • Benefits: Non-invasive, accessible, supports early diagnosis.
    • Impact: Major advancement in Alzheimer’s care and digital diagnostics.

    Source: FDA press release, May 16, 2025



    Source link

    Alzheimers blood clears diagnosis FDA firstever Test
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleFull-Body MRI Detects Cancers Missed by Standard Screenings
    Next Article The medtech IPO window is finally open. Or is it?
    ekass777x
    Healthradar
    • Website

    Related Posts

    Health

    Inside the Bloodbath at the NIH. Sources say that a climate of fear has spread throughout the agency as the Trump administration takes a hatchet to its core functions.

    5. Juni 2025
    Health

    3-Year Exercise Program Improves Colon Cancer Survival Rates

    4. Juni 2025
    Health

    watchOS 12: 3 things I expect to see Tim Cook announce at this year’s WWDC

    3. Juni 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Which Online Poker Game Should You Play?

    31. Mai 20259 Views

    New surgeon general nominee cofounded a16z backed health app with DOGE operative

    1. Juni 20254 Views

    One In Four European Firms Ban Grok AI Chatbot Over Security Concerns

    1. Juni 20252 Views

    Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development

    1. Juni 20252 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    Which Online Poker Game Should You Play?

    31. Mai 20259 Views

    New surgeon general nominee cofounded a16z backed health app with DOGE operative

    1. Juni 20254 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.